ASH 2022 Conference Coverage
Y

ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Maraleucel Administered as Outpatient/Inpatient Treatment in the Community/Non-University Setting in Patients With R/R LBCL

By ASH 2022 Conference Coverage FEATURING Yuliya Linhares
By ASH 2022 Conference Coverage FEATURING Yuliya Linhares
0 views
April 3, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Recommended

AUTOPLAY
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
13:26
Steven Pavletic

Chronic GvHD: Main Complications After ASCT

29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar